raltegravir potassium

Small molecule

raltegravir potassium is one of 5 small molecule programs targeting End Stage Liver Disease. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

End Stage Liver DiseaseActive, not recruiting

End Stage Liver DiseasePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in End Stage Liver Disease

#DrugCompanyPhaseTrials

Hepatitis B Immune Globulin

Merck & Co.

Phase 2

1 2

Myfortic

Novartis

Preclinical

—3

Tocotrienol

FFondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2

1 4

Antibiotics

MMelinta Therapeutics, Inc.

Preclinical

2 5

raltegravir potassium

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Safety and Efficacy2 trials

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00293267·352 enrolled

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00293254·351 enrolled

End Stage Liver Disease1 trial

Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients

Completed·AANRS, Emerging Infectious Diseases·Phase 1/2·NCT01022476·14 enrolled

Clinical Trial1 trial

Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00460382·103 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for raltegravir potassium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — raltegravir potassium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for raltegravir potassium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: Merck & Co.

raltegravir potassium

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Safety and Efficacy2 trials

End Stage Liver Disease1 trial

Clinical Trial1 trial

References

Drug Info

Quick Facts

Related News